The trial is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of G1T28-1 in healthy volunteers, who are currently being enrolled in the Netherlands. The company is conducting
As part of the deal, Genmab will pay an upfront fee of $11m for exclusive rights to use Seattle’s auristatin-based ADC technology with its HuMax-AXL, an antibody targeting
VC-01 has recently secured clearance from the US Food and Drug Administration (FDA) to initiate evaluation in human clinical trials. The company’s stem cell-based therapy has been supported
Arixtra is indicated to treat prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip fracture surgery, including extended prophylaxis, hip
The insulin glargine product is the first insulin treatment approved through the European Medicines Agency’s (EMA’s) biosimilar pathway and the fourth diabetes product approved in the European Union
The US patent no. 8,808,679 provides coverage for anti-tumor payloads and customized linkers used in the company’s Dolaflexin conjugation platform. The second US patent no. 8,815,226 expands its
As part of the deal, Lee’s has secured an exclusive license and right from Abiogen to register, import, market, distribute and sell the Cholecalciferol finished products such as
Currently, EVK-001 is in a Phase III clinical trial for the relief of symptoms related with acute and recurrent gastroparesis in women with diabetes mellitus. A total of
As part of the deal, OnCore will pay NeuroVive an initial upfront payment, development and sales milestones as well as royalties based on future sales. The total value
Endometriosis occurs when cells that line the uterus or womb grow elsewhere in the body. SR16234, a drug candidate of SRI, is a member of a class of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.